Last reviewed · How we verify

Shirley Ryan AbilityLab — Portfolio Competitive Intelligence Brief

Shirley Ryan AbilityLab pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hydromorphone ER Hydromorphone ER marketed Opioid analgesic Mu-opioid receptor (μ-OR) Pain Management
Gralise Gralise marketed Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AdventHealth · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Ajay Wasan, MD, Msc · 1 shared drug class
  4. Alza Corporation, DE, USA · 1 shared drug class
  5. Archimedes Development Ltd · 1 shared drug class
  6. Asbjørn Mohr Drewes · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shirley Ryan AbilityLab:

Cite this brief

Drug Landscape (2026). Shirley Ryan AbilityLab — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shirley-ryan-abilitylab. Accessed 2026-05-14.

Related